ResearcherSheng Jing HospitalActive in the last 2 years

Yaoyuan Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2760-5950; OpenAlex author ID A5031444525. Sources: OpenAlex.

Their work

Papers: 3 (first author 2, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 3

Fecal microbiota transplantation augments 5-fluorouracil efficacy in pancreatic cancer via gut microbiota modulation. First author DOI 10.3389/fmicb.2025.1548027 ↗
Quercetin improves pancreatic cancer chemo-sensitivity by regulating oxidative-inflammatory networks. Co-author DOI 10.1111/jfbc.14453 ↗
An Exploration of Oral-Gut Pathogens Mediating Immune Escape of Pancreatic Cancer via miR-21/PTEN Axis. First author DOI 10.3389/fmicb.2022.928846 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Rui Li · 2 shared papers, 2022–2025 · strength 0.63
- Paper Fecal microbiota transplantation augments 5-fluorouracil efficacy in pancreatic cancer via gut microbiota modulation. DOI 10.3389/fmicb.2025.1548027 ↗
- Paper An Exploration of Oral-Gut Pathogens Mediating Immune Escape of Pancreatic Cancer via miR-21/PTEN Axis. DOI 10.3389/fmicb.2022.928846 ↗
Xiaodong Tan · 1 shared paper, 2025 · strength 0.37
- Paper Fecal microbiota transplantation augments 5-fluorouracil efficacy in pancreatic cancer via gut microbiota modulation. DOI 10.3389/fmicb.2025.1548027 ↗
Shuhong Hou · 1 shared paper, 2022 · strength 0.26
- Paper An Exploration of Oral-Gut Pathogens Mediating Immune Escape of Pancreatic Cancer via miR-21/PTEN Axis. DOI 10.3389/fmicb.2022.928846 ↗
Rui Ma · 1 shared paper, 2022 · strength 0.20
- Paper Quercetin improves pancreatic cancer chemo-sensitivity by regulating oxidative-inflammatory networks. DOI 10.1111/jfbc.14453 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.